FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074425311> ?p ?o ?g. }

• W2074425311 endingPage "2349" @default.
• W2074425311 startingPage "2349" @default.
• W2074425311 abstract "The optimal treatment of acute myeloid leukemia (AML) in first complete remission (CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends myeloablative allogeneic stem cell transplantation (SCT) for poor-risk but not for good-risk AML. Allogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent benefit for intermediate-risk AML.To quantify relapse-free survival (RFS) and overall survival benefit of allogeneic SCT for AML in CR1 overall and also for good-, intermediate-, and poor-risk AML.Systematic review and meta-analysis of prospective trials evaluating allogeneic SCT vs nonallogeneic SCT therapies for AML in CR1. The search used the combined search terms allogeneic; acut* and leukem*/leukaem*/leucem*/leucaem*/aml; myelo* or nonlympho* in the PubMed, Embase, and Cochrane Registry of Controlled Trials databases in March 2009. The search identified 1712 articles.Prospective trials assigning adult patients with AML in CR1 to undergo allogeneic SCT vs nonallogeneic SCT treatment(s) based on donor availability and trials reporting RFS and/or overall survival outcomes on an intention-to-treat, donor vs no-donor basis were identified.Two reviewers independently extracted study characteristics, interventions, and outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were determined.Overall, 24 trials and 6007 patients were analyzed (5951 patients in RFS analyses and 5606 patients in overall survival analyses); 3638 patients were analyzed by cytogenetic risk (547, 2499, and 592 with good-, intermediate-, and poor-risk AML, respectively). Interstudy heterogeneity was not significant. Fixed-effects meta-analysis was performed. Compared with nonallogeneic SCT, the HR of relapse or death with allogeneic SCT for AML in CR1 was 0.80 (95% CI, 0.74-0.86). Significant RFS benefit of allogeneic SCT was documented for poor-risk (HR, 0.69; 95% CI, 0.57-0.84) and intermediate-risk AML (HR, 0.76; 95% CI, 0.68-0.85) but not for good-risk AML (HR, 1.06; 95% CI, 0.80-1.42). The HR of death with allogeneic SCT for AML in CR1 was 0.90 (95% CI, 0.82-0.97). Significant overall survival benefit with allogeneic SCT was documented for poor-risk (HR, 0.73; 95% CI, 0.59-0.90) and intermediate-risk AML (HR, 0.83; 95% CI, 0.74-0.93) but not for good-risk AML (HR, 1.07; 95% CI, 0.83-1.38).Compared with nonallogeneic SCT therapies, allogeneic SCT has significant RFS and overall survival benefit for intermediate- and poor-risk AML but not for good-risk AML in first complete remission." @default.
• W2074425311 created "2016-06-24" @default.
• W2074425311 creator A5013596178 @default.
• W2074425311 creator A5021167699 @default.
• W2074425311 creator A5025894116 @default.
• W2074425311 creator A5029278364 @default.
• W2074425311 creator A5029390145 @default.
• W2074425311 creator A5037291528 @default.
• W2074425311 creator A5047939331 @default.
• W2074425311 creator A5053949970 @default.
• W2074425311 creator A5054037976 @default.
• W2074425311 creator A5056405520 @default.
• W2074425311 creator A5068050082 @default.
• W2074425311 creator A5071023119 @default.
• W2074425311 creator A5074811645 @default.
• W2074425311 creator A5082924494 @default.
• W2074425311 creator A5089395073 @default.
• W2074425311 date "2009-06-10" @default.
• W2074425311 modified "2023-10-18" @default.
• W2074425311 title "Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission" @default.
• W2074425311 cites W1492609361 @default.
• W2074425311 cites W1586473141 @default.
• W2074425311 cites W1629163346 @default.
• W2074425311 cites W1675996391 @default.
• W2074425311 cites W1704551630 @default.
• W2074425311 cites W1709953766 @default.
• W2074425311 cites W1835148062 @default.
• W2074425311 cites W1883249332 @default.
• W2074425311 cites W1953850870 @default.
• W2074425311 cites W1964435302 @default.
• W2074425311 cites W1969708590 @default.
• W2074425311 cites W1979423827 @default.
• W2074425311 cites W2000442546 @default.
• W2074425311 cites W2002542702 @default.
• W2074425311 cites W2010222433 @default.
• W2074425311 cites W2017196865 @default.
• W2074425311 cites W2027909537 @default.
• W2074425311 cites W2035953198 @default.
• W2074425311 cites W2038205401 @default.
• W2074425311 cites W2043216151 @default.
• W2074425311 cites W2048151760 @default.
• W2074425311 cites W2051556928 @default.
• W2074425311 cites W2058531919 @default.
• W2074425311 cites W2075642745 @default.
• W2074425311 cites W2099413874 @default.
• W2074425311 cites W2107328434 @default.
• W2074425311 cites W2112867689 @default.
• W2074425311 cites W2118693086 @default.
• W2074425311 cites W2123081362 @default.
• W2074425311 cites W2124433362 @default.
• W2074425311 cites W2126930838 @default.
• W2074425311 cites W2128812336 @default.
• W2074425311 cites W2142097265 @default.
• W2074425311 cites W2154047650 @default.
• W2074425311 cites W2155153085 @default.
• W2074425311 cites W2158862325 @default.
• W2074425311 cites W2162309072 @default.
• W2074425311 cites W2170846829 @default.
• W2074425311 cites W2315123323 @default.
• W2074425311 cites W2465026282 @default.
• W2074425311 cites W2470285890 @default.
• W2074425311 cites W2916599355 @default.
• W2074425311 cites W62610827 @default.
• W2074425311 doi "https://doi.org/10.1001/jama.2009.813" @default.
• W2074425311 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3163846" @default.
• W2074425311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19509382" @default.
• W2074425311 hasPublicationYear "2009" @default.
• W2074425311 type Work @default.
• W2074425311 sameAs 2074425311 @default.
• W2074425311 citedByCount "770" @default.
• W2074425311 countsByYear W20744253112012 @default.
• W2074425311 countsByYear W20744253112013 @default.
• W2074425311 countsByYear W20744253112014 @default.
• W2074425311 countsByYear W20744253112015 @default.
• W2074425311 countsByYear W20744253112016 @default.
• W2074425311 countsByYear W20744253112017 @default.
• W2074425311 countsByYear W20744253112018 @default.
• W2074425311 countsByYear W20744253112019 @default.
• W2074425311 countsByYear W20744253112020 @default.
• W2074425311 countsByYear W20744253112021 @default.
• W2074425311 countsByYear W20744253112022 @default.
• W2074425311 countsByYear W20744253112023 @default.
• W2074425311 crossrefType "journal-article" @default.
• W2074425311 hasAuthorship W2074425311A5013596178 @default.
• W2074425311 hasAuthorship W2074425311A5021167699 @default.
• W2074425311 hasAuthorship W2074425311A5025894116 @default.
• W2074425311 hasAuthorship W2074425311A5029278364 @default.
• W2074425311 hasAuthorship W2074425311A5029390145 @default.
• W2074425311 hasAuthorship W2074425311A5037291528 @default.
• W2074425311 hasAuthorship W2074425311A5047939331 @default.
• W2074425311 hasAuthorship W2074425311A5053949970 @default.
• W2074425311 hasAuthorship W2074425311A5054037976 @default.
• W2074425311 hasAuthorship W2074425311A5056405520 @default.
• W2074425311 hasAuthorship W2074425311A5068050082 @default.
• W2074425311 hasAuthorship W2074425311A5071023119 @default.
• W2074425311 hasAuthorship W2074425311A5074811645 @default.
• W2074425311 hasAuthorship W2074425311A5082924494 @default.
• W2074425311 hasAuthorship W2074425311A5089395073 @default.

• next